based on the last market figures published by Mintel, which estimated in 2007 that it was worth £38million but projected to reach £46million in 201266.
The Associated Chambers of Commerce and Industry (ASSOCHAM) of India in 2011 estimated the Homoeopathy market globally to be Rs. 263 billion, with a growth rate of 25%. France was found to be the largest contributor. In India the domestic Homoeopathy market size was estimated to be about Rs. 27. 58 billion, likely to grow 30% annually and reach a size of Rs. 46 billion by 201267.
The leading countries exporting homoeopathic medicines are Germany, France and India. Currently, in India there are 414 drug manufacturing units. These companies in organized sector are, professionally managed and equipped with modern facilities and technology. India is exporting homoeopathic products to a number of Asian countries such as Sri Lanka, Bangladesh, Oman, Malaysia, Pakistan, Singapore, Nepal and some European and Latin American countries.
GMP requirements are essential for export of medicines. The framework of the drug industry in India, therefore, identifies quality assurance through regulations and lays down the standards of homoeopathic medicines followed by their publication and dissemination.
Pharmaceutical research offers a high potential for industry to collaborate with the research organizations, universities and institutes. Studies incorporating new substances, standardization, drug proving and clinical verification are a need of the hour for which the CCRH is in the process of exploring options and seeks collaboration and cooperation from the drug manufacturing industry.
Some exotic medicinal plants used commonly along with their botanical names, common names and few clinical conditions, where they are used most commonly are given in Figure 52 to 61.
|<< Previous Page||Back to Contents||Next Page >>|